Vanguard Group’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Vanguard Group’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-642,325	Closed	-$2.47M	–	4574
2023 Q2	$2.47M	Hold	642,325	–	–	﹤0.01%	3588
2023 Q1	$1.94M	Buy	642,325 +15,021	+2%	+$51.9K	﹤0.01%	3681
2022 Q4	$1.29M	Buy	627,304 +4,367	+0.7%	+$13.3K	﹤0.01%	3823
2022 Q3	$2.15M	Hold	622,937	–	–	﹤0.01%	3705
2022 Q2	$2.62M	Hold	622,937	–	–	﹤0.01%	3692
2022 Q1	$1.89M	Sell	622,937 -1,860	-0.3%	-$7.13K	﹤0.01%	3980
2021 Q4	$2.91M	Sell	624,797 -418	-0.1%	-$2.88K	﹤0.01%	3888
2021 Q3	$4.82M	Buy	625,215 +253,441	+68%	+$1.93M	﹤0.01%	3688
2021 Q2	$3.2M	Buy	371,774 +188,515	+103%	+$1.66M	﹤0.01%	3810
2021 Q1	$2.08M	Buy	+183,259	New	+$2.88M	﹤0.01%	3855

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $914M AUM

Vanguard Group's DBTX Position: Q3 2023 in Review

Vanguard Group sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 642,325 shares — an estimated $2.47M sold.

Vanguard Group first reported a position in DBTX in Q1 2021 and held it in 10 quarters. The position peaked at $4.82M in Q3 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Vanguard Group reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Vanguard Group sold 642,325 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.47M.
Vanguard Group first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Vanguard Group's Decibel Therapeutics, Inc. Common Stock position peaked at $4.82M in Q3 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.